Risk stratification strategies are particularly needed for AA prostate cancer patients who disproportionately bear the prostate cancer burden. This study identified TNFRSF9/CD137/4-1BB and PTN as candidate predictive blood markers for prostate cancer mortality among AA patients. This evidence concerns the gene TNFRSF9 and Familial prostate cancer.